18436-71-0

Usage

Uses

Used in Pharmaceutical Industry:
4-Chloro-6-methylquinoline is utilized as an intermediate in the synthesis of various drugs and pharmaceutical compounds, contributing to the development of new medications.
Used in Antimalarial Drug Production:
4-Chloro-6-methylquinoline is employed as a key component in the production of antimalarial drugs, playing a crucial role in combating malaria.
Used in Anticancer Research:
In the field of oncology, 4-Chloro-6-methylquinoline is used as a potential anticancer agent, being investigated for its ability to target and treat cancer cells.
Used in Antiviral Agent Development:
4-Chloro-6-methylquinoline also serves as a component in the development of antiviral agents, indicating its broad-spectrum potential in treating viral infections.
Used in Organic Synthesis:
As a building block, 4-Chloro-6-methylquinoline is used in the synthesis of various heterocyclic compounds and organic molecules, expanding its applications in organic chemistry and related fields.

InChI:InChI=1/C10H8ClN/c1-7-2-3-10-8(6-7)9(11)4-5-12-10/h2-6H,1H3

Upstream product

• 23432-40-8 4-hydroxy-6-methylquinoline 
• 106-49-0 p-toluidine 
• 19056-84-9 diethyl 2-[(p-tolylamino)methylidene]malonate 
• 79607-24-2 6-methyl-4-carbonylquinoline-3-carboxylic acid ethyl ester 
• 23432-40-8 6-methyl-4(1H)-quinolinone 
• 25063-44-9 2,2-Dimethyl-5-(p-tolylamino-methylene)-[1,3]dioxane-4,6-dione 
• 91-62-3 6-methylquinoline 

Downstream Products

• 611-35-8 4-chloroquinoline 
• 1621082-95-8 4-methyl-N-(4-methyl-2-{1-[(4-methylphenyl)sulfonyl]-1Hpyrazol-3-yl}phenyl)benzenesulfonamide 
• 1082748-37-5 C₁₀H₁₁N₃ 
• 826-77-7 4,6-dimethylquinoline 
• 123636-88-4 (S)-2-{4-[(4-Chloro-quinolin-6-ylmethyl)-ethyl-amino]-benzoylamino}-pentanedioic acid 

Relevant academic research and scientific papers

Development of novel quinoline-based sulfonamides as selective cancer-associated carbonic anhydrase isoform ix inhibitors

A new series of quinoline-based benzenesulfonamides (QBS) were developed as potential carbonic anhydrase inhibitors (CAIs). The target QBS CAIs is based on the 4-anilinoquinoline scaffold where the primary sulphonamide functionality was grafted at C4 of t

Synthesis and in vitro evaluation of new benzenesulfonamides as antileishmanial agents

This paper describes the synthesis and the antileishmanial activity of new pyrazolyl benzenesulfonamide derivatives. These were elucidated by spectrometric methods. Some compounds showed a significant in vitro activity against Leishmania amazonensis, highlighting the derivative 1e. These pyrazolyl benzenesulfonamide derivatives did not show any toxicity in murine macrophage.

Further studies on bis-charged tetraazacyclophanes as potent inhibitors of small conductance Ca2+-activated K+ channels

Previously, quinolinium-based tetraazacyclophanes, such as UCL 1684 and UCL 1848, have been shown to be extraordinarily sensitive to changes in chemical structure (especially to the size of the cyclophane system) with respect to activity as potent non-peptidic blockers of the small conductance Ca 2+-activated K+ ion channels (SKCa). The present work has sought to optimize the structure of the linking chains in UCL 1848. We report the synthesis and SKCa channel-blocking activity of 29 analogues of UCL 1848 in which the central CH2 of UCL 1848 is replaced by other groups X or Y = O, S, CF2, CO, CHOH, CC, CHCH, CHMe to explore whether subtle changes in bond length or flexibility can improve potency still further. The possibility of improving potency by introducing ring substituents has also been explored by synthesizing and testing 25 analogues of UCL 1684 and UCL 1848 with substituents (NO2, NH2, CF 3, F, Cl, CH3, OCH3, OCF3, OH) in the 5, 6 or 7 positions of the aminoquinolinium rings. As in our earlier work, each compound was assayed for inhibition of the afterhyperpolarization (AHP) in rat sympathetic neurons, an action mediated by the SK3 subtype of the SK Ca channel. One of the new compounds (39, R7 = Cl, UCL 2053) is twice as potent as UCL 1848 and UCL 1684: seven are comparable in activity.

Synthesis of ring-substituted 4-aminoquinolines and evaluation of their antimalarial activities

A simple two-step synthesis method was used to make 51 B-ring-substituted 4-hydroxyquinolines allowing analysis of the effect of ring substitutions on inhibition of growth of chloroquine sensitive and resistant strains of Plasmodium falciparum, the dominant cause of malaria morbidity. Substituted quinoline rings other than the 7-chloroquinoline ring found in chloroquine were found to have significant activity against the drug-resistant strain of P. falciparum W2.

Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds

The compounds of formula I herein exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, for treating a patient suffering from, or subject to, a physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

4-Piperidino-2-phenylquinolines

Disclosed are compounds of the formula STR1 wherein: R1 and R2 may be either the same or different and each is hydrogen or lower alkyl; and wherein R3 and R4 may be either the same or different and each is hydrogen, halogen, or lower alkyl, with the proviso that R3 and R4 cannot both be hydrogen. These compounds are useful as anticonvulsant or anxiolytic agents.